Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates

References

• Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, Lipkin WI, Negredo AI, Netesov SV, Nichol ST, et al. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol. 2010;155(12):2083–103. doi:10.1007/s00705-010-0814-x.
   PubMed Web of Science ®Google Scholar
• Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011;377(9768):849–62. doi:10.1016/S0140-6736(10)60667-8.
   PubMed Web of Science ®Google Scholar
• Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, Colubri A, Sealfon RSG, Kanneh L, Moigboi A, Momoh M, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med. 2014;371(22):2092–100. doi:10.1056/NEJMoa1411680.
   PubMed Web of Science ®Google Scholar
• Team WER, Aylward B, Barboza P, Bawo L, Bertherat E, Bilivogui P, Blake I, Brennan R, Briand S, Chakauya JM, et al. Ebola virus disease in West Africa–the first 9 months of the epidemic and forward projections. N Engl J Med. 2014;371(16):1481–95. doi:10.1056/NEJMoa1411100.
   PubMed Web of Science ®Google Scholar
• WHO. Ebola virus disease fact sheets. 2016 [accessed 2016 May 27]. https://www.who.int/en/news-room/fact-sheets/detail/ebola-virus-disease
   Google Scholar
• WHO. Ebola virus disease outbreak. 2016 [accessed 2016 Jun 10]. https://www.who.int/csr/disease/ebola/en/
   Google Scholar
• Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, Debré P, Fisher-Hoch SP, McCormick JB, Georges AJ. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med. 1999;5(4):423–26. doi:10.1038/7422.
   PubMed Web of Science ®Google Scholar
• Maruyama T, Rodriguez LL, Jahrling PB, Sanchez A, Khan AS, Nichol ST, Peters CJ, Parren PW, Burton DR. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol. 1999;73:6024–30.
   PubMed Web of Science ®Google Scholar
• Sobarzo A, Perelman E, Groseth A, Dolnik O, Becker S, Lutwama JJ, Dye JM, Yavelsky V, Lobel L, Marks RS. Profiling the native specific human humoral immune response to Sudan Ebola virus strain Gulu by chemiluminescence enzyme-linked immunosorbent assay. Clin Vaccine Immunol. 2012;19(11):1844–52. doi:10.1128/CVI.00363-12.
   PubMedGoogle Scholar
• Flyak AI, Ilinykh PA, Murin CD, Garron T, Shen X, Fusco ML, Hashiguchi T, Bornholdt ZA, Slaughter JC, Sapparapu G, et al. Mechanism of human antibody-mediated neutralization of Marburg virus. Cell. 2015;160(5):893–903. doi:10.1016/j.cell.2015.01.031.
   PubMed Web of Science ®Google Scholar
• Flyak AI, Shen X, Murin CD, Turner HL, David JA, Fusco ML, Lampley R, Kose N, Ilinykh PA, Kuzmina N, et al. Cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection. Cell. 2016;164(3):392–405. doi:10.1016/j.cell.2015.12.022.
   PubMed Web of Science ®Google Scholar
• Bornholdt ZA, Turner HL, Murin CD, Li W, Sok D, Souders CA, Piper AE, Goff A, Shamblin JD, Wollen SE, et al. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science. 2016;351(6277):1078–83. doi:10.1126/science.aad5788.
   PubMed Web of Science ®Google Scholar
• Rosenke K, Bounds CE, Hanley PW, Saturday G, Sullivan E, Wu H, Jiao J-A, Feldmann H, Schmaljohn C, Safronetz D. Human polyclonal antibodies produced by transchromosomal cattle provide partial protection against lethal zaire ebolavirus challenge in rhesus macaques. J Infect Dis. 2018;218(suppl_5):S658–S661. doi:10.1093/infdis/jiy430.
   PubMedGoogle Scholar
• Qiu X, Audet J, Wong G, Pillet S, Bello A, Cabral T, Strong JE, Plummer F, Corbett CR, Alimonti JB, et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med. 2012;4(138):138ra81. doi:10.1126/scitranslmed.3003876.
   PubMed Web of Science ®Google Scholar
• McElroy AK, Akondy RS, Davis CW, Ellebedy AH, Mehta AK, Kraft CS, Lyon GM, Ribner BS, Varkey J, Sidney J, et al. Human Ebola virus infection results in substantial immune activation. Proc Natl Acad Sci USA. 2015;112(15):4719–24. doi:10.1073/pnas.1502619112.
   PubMed Web of Science ®Google Scholar
• Stonier SW, Herbert AS, Kuehne AI, Sobarzo A, Habibulin P, Dahan CVA, James RM, Egesa M, Cose S, Lutwama JJ, et al. Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses. J Exp Med. 2017;214(9):2563–72. doi:10.1084/jem.20170161.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis. 2002;8(5):503–07. doi:10.3201/eid0805.010284.
   PubMed Web of Science ®Google Scholar
• Rao M, Bray M, Alving CR, Jahrling P, Matyas GR. Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells. J Virol. 2002;76(18):9176–85. doi:10.1128/jvi.76.18.9176-9185.2002.
   PubMed Web of Science ®Google Scholar
• Marzi A, Halfmann P, Hill-Batorski L, Feldmann F, Shupert WL, Neumann G, Feldmann H, Kawaoka Y. Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates. Science. 2015;348(6233):439–42. doi:10.1126/science.aaa4919.
   PubMed Web of Science ®Google Scholar
• Herbert AS, Kuehne AI, Barth JF, Ortiz RA, Nichols DK, Zak SE, Stonier SW, Muhammad MA, Bakken RR, Prugar LI, et al. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol. 2013;87(9):4952–64. doi:10.1128/JVI.03361-12.
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang Z-Y, Roederer M, Koup RA, Jahrling PB, Nabel GJ. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 2003;424(6949):681–84. doi:10.1038/nature01876.
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, Custers JHHV, Popernack PM, Yang Z-Y, Pau MG, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med. 2006;3(6):e177. doi:10.1371/journal.pmed.0030177.
   PubMed Web of Science ®Google Scholar
• Wu S, Kroeker A, Wong G, He S, Hou L, Audet J, Wei H, Zhang Z, Fernando L, Soule G, et al. An adenovirus vaccine expressing Ebola virus variant makona glycoprotein is efficacious in guinea pigs and nonhuman primates. J Infect Dis. 2016;214(suppl 3):S326–S332. doi:10.1093/infdis/jiw250.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, Honko A, Johnson J, Mulangu S, Pau MG, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol. 2011;85(9):4222–33. doi:10.1128/JVI.02407-10.
   PubMed Web of Science ®Google Scholar
• Callendret B, Vellinga J, Wunderlich K, Rodriguez A, Steigerwald R, Dirmeier U, Cheminay C, Volkmann A, Brasel T, Carrion R, et al. A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. PLoS One. 2018;13(2):e0192312. doi:10.1371/journal.pone.0192312.
   PubMed Web of Science ®Google Scholar
• Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, Hensley L, Ammendola V, Abbate A, Grazioli F, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014;20(10):1126–29. doi:10.1038/nm.3702.
   PubMed Web of Science ®Google Scholar
• Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, Holman DH, Dong JY, Pratt WD. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol. 2008;15(3):460–67. doi:10.1128/CVI.00431-07.
   PubMed Web of Science ®Google Scholar
• Pratt WD, Wang D, Nichols DK, Luo M, Woraratanadharm J, Dye JM, Holman DH, Dong JY. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol. 2010;17(4):572–81. doi:10.1128/CVI.00467-09.
   PubMed Web of Science ®Google Scholar
• Domi A, Feldmann F, Basu R, McCurley N, Shifflett K, Emanuel J, Hellerstein MS, Guirakhoo F, Orlandi C, Flinko R, et al. A single dose of modified vaccinia ankara expressing ebola virus like particles protects nonhuman primates from lethal Ebola virus challenge. Sci Rep. 2018;8(1):864. doi:10.1038/s41598-017-19041-y.
   PubMed Web of Science ®Google Scholar
• Grant-Klein RJ, Altamura LA, Badger CV, Bounds CE, Van Deusen NM, Kwilas SA, Vu HA, Warfield KL, Hooper JW, Hannaman D, et al. Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges. Hum Vaccin Immunother. 2015;11(8):1991–2004. doi:10.1080/21645515.2015.1039757.
   PubMed Web of Science ®Google Scholar
• Patel A, Reuschel EL, Kraynyak KA, Racine T, Park DH, Scott VL, Audet J, Amante D, Wise MC, Keaton AA, et al. Protective efficacy and long-term immunogenicity in cynomolgus macaques by Ebola virus glycoprotein synthetic DNA vaccines. J Infect Dis. 2019;219(4):544–55. doi:10.1093/infdis/jiy537.
   PubMed Web of Science ®Google Scholar
• Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis. 2007;196 Suppl 2(Suppl 2):S430–7. doi:10.1086/520583.
   PubMedGoogle Scholar
• Warfield KL, Howell KA, Vu H, Geisbert J, Wong G, Shulenin S, Sproule S, Holtsberg FW, Leung DW, Amarasinghe GK, et al. Role of antibodies in protection against Ebola virus in nonhuman primates immunized with three vaccine platforms. J Infect Dis. 2018;218(suppl_5):S553–S564. doi:10.1093/infdis/jiy316.
   PubMedGoogle Scholar
• Marzi A, Murphy AA, Feldmann F, Parkins CJ, Haddock E, Hanley PW, Emery MJ, Engelmann F, Messaoudi I, Feldmann H, et al. Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection. Sci Rep. 2016;6:21674. doi:10.1038/srep21674.
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Rollin PE, Tate MK, Yang L, Zaki SR, Shieh W-J, Murphy BR, Collins PL, Sanchez A. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol. 2007;81(12):6379–88. doi:10.1128/JVI.00105-07.
   PubMed Web of Science ®Google Scholar
• Meyer M, Garron T, Lubaki NM, Mire CE, Fenton KA, Klages C, Olinger GG, Geisbert TW, Collins PL, Bukreyev A. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses. J Clin Invest. 2015;125(8):3241–55. doi:10.1172/JCI81532.
   PubMed Web of Science ®Google Scholar
• Blaney JE, Marzi A, Willet M, Papaneri AB, Wirblich C, Feldmann F, Holbrook M, Jahrling P, Feldmann H, Schnell MJ, et al. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog. 2013;9(5):e1003389. doi:10.1371/journal.ppat.1003389.
   PubMed Web of Science ®Google Scholar
• Willet M, Kurup D, Papaneri A, Wirblich C, Hooper JW, Kwilas SA, Keshwara R, Hudacek A, Beilfuss S, Rudolph G, et al. Preclinical development of inactivated rabies virus-based polyvalent vaccine against rabies and filoviruses. J Infect Dis. 2015;212(Suppl 2):S414–24. doi:10.1093/infdis/jiv251.
   PubMed Web of Science ®Google Scholar
• Jones SM, Feldmann H, Ströher U, Geisbert JB, Fernando L, Grolla A, Klenk H-D, Sullivan NJ, Volchkov VE, Fritz EA, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005;11(7):786–90. doi:10.1038/nm1258.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A, Feldmann H. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol. 2009;83(14):7296–304. doi:10.1128/JVI.00561-09.
   PubMed Web of Science ®Google Scholar
• Falzarano D, Feldmann F, Grolla A, Leung A, Ebihara H, Strong JE, Marzi A, Takada A, Jones S, Gren J, et al. Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. J Infect Dis. 2011;204(Suppl 3):S1082–9. doi:10.1093/infdis/jir350.
   PubMedGoogle Scholar
• Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000;408(6812):605–09. doi:10.1038/35046108.
   PubMed Web of Science ®Google Scholar
• Fausther-Bovendo H, Vieillard V, Sagan S, Bismuth G, Debré P. HIV gp41 engages gC1qR on CD4+ T cells to induce the expression of an NK ligand through the PIP3/H2O2 pathway. PLoS Pathog. 2010;6(5):e1000904. doi:10.1371/journal.ppat.1000975.
   PubMedGoogle Scholar
• Ignatyev GM, Agafonov AP, Streltsova MA, Kashentseva EA. Inactivated Marburg virus elicits a nonprotective immune response in Rhesus monkeys. J Biotechnol. 1996;44(1–3):111–18. doi:10.1016/0168-1656(95)00104-2.
   PubMed Web of Science ®Google Scholar
• Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology. 1998;251(1):28–37. doi:10.1006/viro.1998.9367.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Bailey M, Geisbert JB, Asiedu C, Roederer M, Grazia-Pau M, Custers J, Jahrling P, Goudsmit J, Koup R, et al. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J Virol. 2010;84(19):10386–94. doi:10.1128/JVI.00594-10.
   PubMed Web of Science ®Google Scholar
• Riemenschneider J, Garrison A, Geisbert J, Jahrling P, Hevey M, Negley D, Schmaljohn A, Lee J, Hart MK, Vanderzanden L, et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine. 2003;21(25–26):4071–80. doi:10.1016/s0264-410x(03)00362-1.
   PubMed Web of Science ®Google Scholar
• Swenson DL, Warfield KL, Larsen T, Alves DA, Coberley SS, Bavari S. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev Vaccines. 2008;7(4):417–29. doi:10.1586/14760584.7.4.417.
   PubMed Web of Science ®Google Scholar
• Dye JM, Warfield K, Wells J, Unfer R, Shulenin S, Vu H, Nichols D, Aman M, Bavari S. Virus-like particle vaccination protects nonhuman primates from lethal aerosol exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol challenges). Viruses. 2016;8(4):94. doi:10.3390/v8040094.
   PubMed Web of Science ®Google Scholar
• Lupton HW, Lambert RD, Bumgardner DL, Moe JB, Eddy GA. Inactivated vaccine for Ebola virus efficacious in guineapig model. Lancet. 1980;2(8207):1294–95. doi:10.1016/s0140-6736(80)92352-1.
   PubMed Web of Science ®Google Scholar
• Warfield KL, Swenson DL, Olinger GG, Kalina WV, Viard M, Aitichou M, Chi X, Ibrahim S, Blumenthal R, Raviv Y, et al. Ebola virus inactivation with preservation of antigenic and structural integrity by a photoinducible alkylating agent. J Infect Dis. 2007;196(Suppl 2):S276–83. doi:10.1086/520605.
   PubMed Web of Science ®Google Scholar
• Hevey M, Negley D, Geisbert J, Jahrling P, Schmaljohn A. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology. 1997;239(1):206–16. doi:10.1006/viro.1997.8883.
   PubMed Web of Science ®Google Scholar
• Warfield KL, Swenson DL, Negley DL, Schmaljohn AL, Aman MJ, Bavari S. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine. 2004;22(25–26):3495–502. doi:10.1016/j.vaccine.2004.01.063.
   PubMed Web of Science ®Google Scholar
• Halfmann P, Kim JH, Ebihara H, Noda T, Neumann G, Feldmann H, Kawaoka Y. Generation of biologically contained Ebola viruses. Proc Natl Acad Sci USA. 2008;105(4):1129–33. doi:10.1073/pnas.0708057105.
   PubMed Web of Science ®Google Scholar
• Halfmann P, Ebihara H, Marzi A, Hatta Y, Watanabe S, Suresh M, Neumann G, Feldmann H, Kawaoka Y. Replication-deficient ebolavirus as a vaccine candidate. J Virol. 2009;83(8):3810–15. doi:10.1128/JVI.00074-09.
   PubMed Web of Science ®Google Scholar
• Marzi A, Feldmann H. Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines. 2014;13(4):521–31. doi:10.1586/14760584.2014.885841.
   PubMed Web of Science ®Google Scholar
• Lehrer AT, Wong T-AS, Lieberman MM, Humphreys T, Clements DE, Bakken RR, Hart MK, Pratt WD, Dye JM. Recombinant proteins of Zaire ebolavirus induce potent humoral and cellular immune responses and protect against live virus infection in mice. Vaccine. 2018;36(22):3090–100. doi:10.1016/j.vaccine.2017.01.068.
   PubMed Web of Science ®Google Scholar
• Liu Y, Ye L, Lin F, Gomaa Y, Flyer D, Carrion R, Patterson JL, Prausnitz MR, Smith G, Glenn G, et al. Intradermal vaccination with adjuvanted Ebola virus soluble glycoprotein subunit vaccine by microneedle patches protects mice against lethal Ebola virus challenge. J Infect Dis. 2018;218(suppl_5):S545–S552. doi:10.1093/infdis/jiy267.
   PubMedGoogle Scholar
• Liu Y, Ye L, Lin F, Gomaa Y, Flyer D, Carrion R, Patterson JL, Prausnitz MR, Smith G, Glenn G, et al. Intradermal immunization by Ebola virus GP subunit vaccines using microneedle patches protects mice against lethal EBOV challenge. Sci Rep. 2018;8(1):11193. doi:10.1038/s41598-018-29135-w.
   PubMedGoogle Scholar
• Konduru K, Shurtleff AC, Bradfute SB, Nakamura S, Bavari S, Kaplan G, Tsuji M. Ebolavirus glycoprotein Fc fusion protein protects guinea pigs against lethal challenge. PLoS One. 2016;11(9):e0162446. doi:10.1371/journal.pone.0162446.
   PubMed Web of Science ®Google Scholar
• Mire CE, Geisbert TW. Viral-vectored vacciens to control pathogenic filoviruses. In: Luashevich IS, Shirwan H, editors. Novel technologies for vaccine developement. Wien (Vienna): Springer-Verlag; 2014. p. 33–60.
   Google Scholar
• Hoenen T, Groseth A, Feldmann H. Current ebola vaccines. Expert Opin Biol Ther. 2012;12(7):859–72. doi:10.1517/14712598.2012.685152.
   PubMed Web of Science ®Google Scholar
• Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology. 1997;239(2):389–401. doi:10.1006/viro.1997.8878.
   PubMed Web of Science ®Google Scholar
• Wilson JA, Hevey M, Bakken R, Guest S, Bray M, Schmaljohn AL, Hart MK. Epitopes involved in antibody-mediated protection from Ebola virus. Science. 2000;287(5458):1664–66. doi:10.1126/science.287.5458.1664.
   PubMed Web of Science ®Google Scholar
• Maruyama T, Parren PW, Sanchez A, Rensink I, Rodriguez LL, Khan AS, Peters CJ, Burton DR. Recombinant human monoclonal antibodies to Ebola virus. J Infect Dis. 1999;179 Suppl 1(Suppl 1):S235–9. doi:10.1086/514280.
   PubMedGoogle Scholar
• Parren PWHI, Geisbert TW, Maruyama T, Jahrling PB, Burton DR. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol. 2002;76(12):6408–12. doi:10.1128/jvi.76.12.6408-6412.2002.
   PubMed Web of Science ®Google Scholar
• Olinger GG, Bailey MA, Dye JM, Bakken R, Kuehne A, Kondig J, Wilson J, Hogan RJ, Hart MK. Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. J Virol. 2005;79(22):14189–96. doi:10.1128/JVI.79.22.14189-14196.2005.
   PubMed Web of Science ®Google Scholar
• Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, Sanchez A, Jahrling PB, Smith JF. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine. 2000;19(1):142–53. doi:10.1016/s0264-410x(00)00113-4.
   PubMed Web of Science ®Google Scholar
• Ren S, Wei Q, Cai L, Yang X, Xing C, Tan F, Leavenworth JW, Liang S, Liu W. Alphavirus replicon DNA vectors expressing Ebola GP and VP40 antigens induce humoral and cellular immune responses in mice. Front Microbiol. 2018;8:2662. doi:10.3389/fmicb.2017.02662.
   PubMed Web of Science ®Google Scholar
• Öhlund P, García-Arriaza J, Zusinaite E, Szurgot I, Männik A, Kraus A, Ustav M, Merits A, Esteban M, Liljeström P, et al. DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune responses that can be further improved by a recombinant MVA boost. Sci Rep. 2018;8(1):12459. doi:10.1038/s41598-018-31003-6.
   PubMedGoogle Scholar
• Yang Y, Greenough K, Wilson JM. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther. 1996;3:412–20.
   PubMed Web of Science ®Google Scholar
• Yang Y, Li Q, Ertl HC, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol. 1995;69:2004–15.
   PubMed Web of Science ®Google Scholar
• Kass-Eisler A, Leinwand L, Gall J, Bloom B, Falck-Pedersen E. Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther. 1996;3:154–62.
   PubMed Web of Science ®Google Scholar
• Kobinger GP, Feldmann H, Zhi Y, Schumer G, Gao G, Feldmann F, Jones S, Wilson JM. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology. 2006;346(2):394–401. doi:10.1016/j.virol.2005.10.042.
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, Johnson J, Honko A, Olinger G, Bailey M, Geisbert JB, et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med. 2011;17(9):1128–31. doi:10.1038/nm.2447.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine. 2010;29(2):304–13. doi:10.1016/j.vaccine.2010.10.037.
   PubMed Web of Science ®Google Scholar
• Zhu F-C, Hou L-H, Li J-X, Wu S-P, Liu P, Zhang G-R, Hu Y-M, Meng F-Y, Xu -J-J, Tang R, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet. 2015;385(9984):2272–79. doi:10.1016/S0140-6736(15)60553-0.
   PubMed Web of Science ®Google Scholar
• Zhu F-C, Wurie AH, Hou L-H, Liang Q, Li Y-H, Russell JBW, Wu S-P, Li J-X, Hu Y-M, Guo Q, et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2017;389(10069):621–28. doi:10.1016/S0140-6736(16)32617-4.
   PubMed Web of Science ®Google Scholar
• Li J-X, Hou L-H, Meng F-Y, Wu S-P, Hu Y-M, Liang Q, Chu K, Zhang Z, Xu -J-J, Tang R, et al. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob Health. 2017;5(3):e324–e334. doi:10.1016/S2214-109X(16)30367-9.
   PubMed Web of Science ®Google Scholar
• De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, Cochet C, Estoppey D, Steiner-Monard V, Lonchampt S, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2016;16(3):311–20. doi:10.1016/S1473-3099(15)00486-7.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, DeZure AD, Stanley DA, Coates EE, Novik L, Enama ME, Berkowitz NM, Hu Z, Joshi G, Ploquin A, et al. Chimpanzee adenovirus vector Ebola vaccine. N Engl J Med. 2017;376(10):928–38. doi:10.1056/NEJMoa1410863.
   PubMed Web of Science ®Google Scholar
• Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, Imoukhuede EB, Payne R, Fehling SK, Strecker T, et al. A monovalent Chimpanzee adenovirus Ebola vaccine boosted with MVA. N Engl J Med. 2016;374(17):1635–46. doi:10.1056/NEJMoa1411627.
   PubMed Web of Science ®Google Scholar
• Venkatraman N, Ndiaye BP, Bowyer G, Wade D, Sridhar S, Wright D, Powlson J, Ndiaye I, Dièye S, Thompson C, et al. Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen - ChAd3-EBO-Z followed by MVA-EBO-Z in healthy adults in the UK and Senegal. J Infect Dis. 2019 April 15;219(8):1187–1197.
   PubMed Web of Science ®Google Scholar
• Milligan ID, Gibani MM, Sewell R, Clutterbuck EA, Campbell D, Plested E, Nuthall E, Voysey M, Silva-Reyes L, McElrath MJ, et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA. 2016;315(15):1610–23. doi:10.1001/jama.2016.4218.
   PubMed Web of Science ®Google Scholar
• Winslow RL, Milligan ID, Voysey M, Luhn K, Shukarev G, Douoguih M, Snape MD. Immune responses to novel adenovirus type 26 and modified vaccinia virus ankara-vectored Ebola vaccines at 1 year. JAMA. 2017;317(10):1075–77. doi:10.1001/jama.2016.20644.
   PubMed Web of Science ®Google Scholar
• Anywaine Z, Whitworth H, Kaleebu P, Praygod G, Shukarev G, Manno D, Kapiga S, Grosskurth H, Kalluvya S, Bockstal V, et al. Safety and Immunogenicity of heterologous Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Uganda and Tanzania. J Infect Dis. 2019;220:46–56. doi:10.1093/infdis/jiz070.
   PubMed Web of Science ®Google Scholar
• Mutua G, Anzala O, Luhn K, Robinson C, Bockstal V, Anumendem D, Douoguih M. Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Nairobi, Kenya. J Infect Dis. 2019;220:57–67. doi:10.1093/infdis/jiz071.
   PubMed Web of Science ®Google Scholar
• Suschak JJ, Wang S, Fitzgerald KA, Lu S. Identification of aim2 as a sensor for DNA vaccines. J Immunol. 2015;194(2):630–36. doi:10.4049/jimmunol.1402530.
   PubMed Web of Science ®Google Scholar
• Suschak JJ, Wang S, Fitzgerald KA, Lu S. A cGAS-Independent STING/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines. J Immunol. 2016;196(1):310–16. doi:10.4049/jimmunol.1501836.
   PubMed Web of Science ®Google Scholar
• Dupuy LC, Richards MJ, Ellefsen B, Chau L, Luxembourg A, Hannaman D, Livingston BD, Schmaljohn CS. A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates. Clin Vaccine Immunol. 2011;18(5):707–16. doi:10.1128/CVI.00030-11.
   PubMed Web of Science ®Google Scholar
• Dupuy LC, Richards MJ, Reed DS, Schmaljohn CS. Immunogenicity and protective efficacy of a DNA vaccine against Venezuelan equine encephalitis virus aerosol challenge in nonhuman primates. Vaccine. 2010;28(46):7345–50. doi:10.1016/j.vaccine.2010.09.005.
   PubMed Web of Science ®Google Scholar
• Hooper JW, Moon JE, Paolino KM, Newcomer R, McLain DE, Josleyn M, Hannaman D, Schmaljohn C. A phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation. Clin Microbiol Infect. 2014;20(Suppl 5):110–17. doi:10.1111/1469-0691.12553.
   PubMed Web of Science ®Google Scholar
• Hannaman D, Dupuy LC, Ellefsen B, Schmaljohn CS. A phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation. Vaccine. 2016;34(31):3607–12. doi:10.1016/j.vaccine.2016.04.077.
   PubMed Web of Science ®Google Scholar
• Xu L, Sanchez A, Yang Z, Zaki SR, Nabel EG, Nichol ST, Nabel GJ. Immunization for Ebola virus infection. Nat Med. 1998;4:37–42.
   PubMed Web of Science ®Google Scholar
• Vanderzanden L, Bray M, Fuller D, Roberts T, Custer D, Spik K, Jahrling P, Huggins J, Schmaljohn A, Schmaljohn C. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology. 1998;246(1):134–44. doi:10.1006/viro.1998.9176.
   PubMed Web of Science ®Google Scholar
• Suschak JJ, Bagley K, Shoemaker CJ, Six C, Kwilas S, Dupuy LC, Schmaljohn CS. The genetic adjuvants interleukin-12 and granulocyte-macrophage colony stimulating factor enhance the immunogenicity of an Ebola virus deoxyribonucleic acid vaccine in mice. J Infect Dis. 2018. doi:10.1093/infdis/jiy378.
   PubMed Web of Science ®Google Scholar
• Li W, Ye L, Carrion R, Mohan GS, Nunneley J, Staples H, Ticer A, Patterson JL, Compans RW, Yang C. Characterization of immune responses induced by Ebola Virus Glycoprotein (GP) and truncated GP isoform DNA vaccines and protection against lethal Ebola virus challenge in mice. J Infect Dis. 2015;212(Suppl 2):S398–403. doi:10.1093/infdis/jiv186.
   PubMed Web of Science ®Google Scholar
• Shedlock DJ, Aviles J, Talbott KT, Wong G, Wu SJ, Villarreal DO, Myles DJ, Croyle MA, Yan J, Kobinger GP, et al. Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol Ther. 2013;21(7):1432–44. doi:10.1038/mt.2013.61.
   PubMed Web of Science ®Google Scholar
• Grant-Klein RJ, Van Deusen NM, Badger CV, Hannaman D, Dupuy LC, Schmaljohn CS. A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge. Hum Vaccin Immunother. 2012;8(11):1703–06. doi:10.4161/hv.21873.
   PubMed Web of Science ®Google Scholar
• Gustafsson C, Govindarajan S, Minshull J. Codon bias and heterologous protein expression. Trends Biotechnol. 2004;22(7):346–53. doi:10.1016/j.tibtech.2004.04.006.
   PubMed Web of Science ®Google Scholar
• Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. 2006;13(11):1267–77. doi:10.1128/CVI.00162-06.
   PubMed Web of Science ®Google Scholar
• Sarwar UN, Costner P, Enama ME, Berkowitz N, Hu Z, Hendel CS, Sitar S, Plummer S, Mulangu S, Bailer RT, et al. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis. 2015;211(4):549–57. doi:10.1093/infdis/jiu511.
   PubMed Web of Science ®Google Scholar
• Kibuuka H, Berkowitz NM, Millard M, Enama ME, Tindikahwa A, Sekiziyivu AB, Costner P, Sitar S, Glover D, Hu Z, et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet. 2015;385(9977):1545–54. doi:10.1016/S0140-6736(14)62385-0.
   PubMed Web of Science ®Google Scholar
• Warfield KL, Posten NA, Swenson DL, Olinger GG, Esposito D, Gillette WK, Hopkins RF, Costantino J, Panchal RG, Hartley JL, et al. Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J Infect Dis. 2007;196(Suppl 2):S421–9. doi:10.1086/520612.
   PubMed Web of Science ®Google Scholar
• Ye L, Lin J, Sun Y, Bennouna S, Lo M, Wu Q, Bu Z, Pulendran B, Compans RW, Yang C. Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology. 2006;351(2):260–70. doi:10.1016/j.virol.2006.03.021.
   PubMed Web of Science ®Google Scholar
• Habte HH, Mall AS, de Beer C, Lotz ZE, Kahn D. The role of crude human saliva and purified salivary MUC5B and MUC7 mucins in the inhibition of Human Immunodeficiency Virus type 1 in an inhibition assay. Virol J. 2006;3:31. doi:10.1186/1743-422X-3-99.
   PubMed Web of Science ®Google Scholar
• Martinez O, Tantral L, Mulherkar N, Chandran K, Basler CF. Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles. J Infect Dis. 2011;204(Suppl 3):S825–32. doi:10.1093/infdis/jir295.
   PubMedGoogle Scholar
• Warfield KL, Bosio CM, Welcher BC, Deal EM, Mohamadzadeh M, Schmaljohn A, Aman MJ, Bavari S. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci USA. 2003;100(26):15889–94. doi:10.1073/pnas.2237038100.
   PubMed Web of Science ®Google Scholar
• Warfield KL, Olinger G, Deal EM, Swenson DL, Bailey M, Negley DL, Hart MK, Bavari S. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol. 2005;175(2):1184–91. doi:10.4049/jimmunol.175.2.1184.
   PubMed Web of Science ®Google Scholar
• Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine. 2005;23(23):3033–42. doi:10.1016/j.vaccine.2004.11.070.
   PubMed Web of Science ®Google Scholar
• Warfield KL, Aman MJ. Advances in virus-like particle vaccines for filoviruses. J Infect Dis. 2011;204(Suppl 3):S1053–9. doi:10.1093/infdis/jir346.
   PubMed Web of Science ®Google Scholar
• Martins K, Carra JH, Cooper CL, Kwilas SA, Robinson CG, Shurtleff AC, Schokman RD, Kuehl KA, Wells JB, Steffens JT, et al. Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein. Viral Immunol. 2015;28(1):62–70. doi:10.1089/vim.2014.0071.
   PubMed Web of Science ®Google Scholar
• Bengtsson KL, Song H, Stertman L, Liu Y, Flyer DC, Massare MJ, Xu R-H, Zhou B, Lu H, Kwilas SA, et al. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Vaccine. 2016;34(16):1927–35. doi:10.1016/j.vaccine.2016.02.033.
   PubMed Web of Science ®Google Scholar
• Novavax. Novavax Ebola/Makona Glycoprotein Nanoparticle Vaccine Candidate Update: NHP and Clinical Data, in WHO 5th Teleconference on Ebola Vaccine Clinical Trials. 2015.
   Google Scholar
• Friedrich BM, Trefry JC, Biggins JE, Hensley LE, Honko AN, Smith DR, Olinger GG. Potential vaccines and post-exposure treatments for filovirus infections. Viruses. 2012;4(9):1619–50. doi:10.3390/v4091619.
   PubMed Web of Science ®Google Scholar
• Rizvanov AA, van Geelen AGM, Morzunov S, Otteson EW, Bohlman C, Pari GS, St Jeor SC. Generation of a recombinant cytomegalovirus for expression of a hantavirus glycoprotein. J Virol. 2003;77(22):12203–10. doi:10.1128/jvi.77.22.12203-12210.2003.
   PubMed Web of Science ®Google Scholar
• Humphreys IR, Sebastian S. Novel viral vectors in infectious diseases. Immunology. 2018;153(1):1–9. doi:10.1111/imm.12829.
   PubMed Web of Science ®Google Scholar
• Moreno Y, Gros -P-P, Tam M, Segura M, Valanparambil R, Geary TG, Stevenson MM. Proteomic analysis of excretory-secretory products of Heligmosomoides polygyrus assessed with next-generation sequencing transcriptomic information. PLoS Negl Trop Dis. 2011;5(10):e1275. doi:10.1371/journal.pntd.0001370.
   PubMed Web of Science ®Google Scholar
• Klenerman P, Oxenius A. T cell responses to cytomegalovirus. Nat Rev Immunol. 2016;16(6):367–77. doi:10.1038/nri.2016.38.
   PubMed Web of Science ®Google Scholar
• Tsuda Y, Parkins CJ, Caposio P, Feldmann F, Botto S, Ball S, Messaoudi I, Cicin-Sain L, Feldmann H, Jarvis MA. A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose. Vaccine. 2015;33(19):2261–66. doi:10.1016/j.vaccine.2015.03.029.
   PubMed Web of Science ®Google Scholar
• Yang L, Sanchez A, Ward JM, Murphy BR, Collins PL, Bukreyev A. A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals. Virology. 2008;377(2):255–64. doi:10.1016/j.virol.2008.04.029.
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Yang L, Zaki SR, Shieh W-J, Rollin PE, Murphy BR, Collins PL, Sanchez A. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol. 2006;80(5):2267–79. doi:10.1128/JVI.80.5.2267-2279.2006.
   PubMed Web of Science ®Google Scholar
• Weidenbach K, Nickel L, Neve H, Alkhnbashi OS, Künzel S, Kupczok A, Bauersachs T, Cassidy L, Tholey A, Backofen R, et al. Methanosarcina Spherical Virus, a Novel Archaeal Lytic Virus Targeting Methanosarcina Strains. J Virol. 2017;91(22). doi:10.1128/JVI.00955-17.
   PubMed Web of Science ®Google Scholar
• Yano T, Fukuta M, Maeda C, Akachi S, Matsuno Y, Yamadera M, Kobayashi A, Nagai Y, Kusuhara H, Kobayashi T, et al. Epidemiological investigation and seroprevalence of human parainfluenza virus in Mie Prefecture in Japan during 2009-2013. Jpn J Infect Dis. 2014;67:506–08.
   PubMed Web of Science ®Google Scholar
• Bukreyev AA, Dinapoli JM, Yang L, Murphy BR, Collins PL. Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic. Virology. 2010;399(2):290–98. doi:10.1016/j.virol.2010.01.015.
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Marzi A, Feldmann F, Zhang L, Yang L, Ward JM, Dorward DW, Pickles RJ, Murphy BR, Feldmann H, et al. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology. 2009;383(2):348–61. doi:10.1016/j.virol.2008.09.030.
   PubMed Web of Science ®Google Scholar
• Blaney JE, Wirblich C, Papaneri AB, Johnson RF, Myers CJ, Juelich TL, Holbrook MR, Freiberg AN, Bernbaum JG, Jahrling PB, et al. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol. 2011;85(20):10605–16. doi:10.1128/JVI.00558-11.
   PubMed Web of Science ®Google Scholar
• Papaneri AB, Wirblich C, Cann JA, Cooper K, Jahrling PB, Schnell MJ, Blaney JE. A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence. Virology. 2012;434(1):18–26. doi:10.1016/j.virol.2012.07.020.
   PubMed Web of Science ®Google Scholar
• Keshwara R, Hagen KR, Abreu-Mota T, Papaneri AB, Liu D, Wirblich C, Johnson RF, Schnell MJ, García-Sastre A. Recombinant rabies virus expressing the Marburg virus glycoprotein is dependent upon for protection against Marburg virus disease in a murine model. J Virol. 2018;93. doi:10.1128/JVI.01865-18.
   Web of Science ®Google Scholar
• Walsh PD, Kurup D, Hasselschwert DL, Wirblich C, Goetzmann JE, Schnell MJ. The final (Oral Ebola) vaccine trial on captive Chimpanzees? Sci Rep. 2017;7:43339. doi:10.1038/srep43339.
   PubMed Web of Science ®Google Scholar
• Wagner RRR. Rhabidoviridae: The Viruses and Their Replication. In: Fields BNK, editor. Fields Virology. New York (NY): Lippincott-Raven; 1996. p. 1121–36.
   Google Scholar
• Schnell MJ, Buonocore L, Kretzschmar E, Johnson E, Rose JK. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci USA. 1996;93(21):11359–65. doi:10.1073/pnas.93.21.11359.
   PubMed Web of Science ®Google Scholar
• Rose NF, Roberts A, Buonocore L, Rose JK. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol. 2000;74(23):10903–10. doi:10.1128/jvi.74.23.10903-10910.2000.
   PubMed Web of Science ®Google Scholar
• Rose NF, Marx PA, Luckay A, Nixon DF, Moretto WJ, Donahoe SM, Montefiori D, Roberts A, Buonocore L, Rose JK. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell. 2001;106(5):539–49. doi:10.1016/s0092-8674(01)00482-2.
   PubMed Web of Science ®Google Scholar
• Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Möller P, Wagner R, Volchkov V, Klenk H-D, Feldmann H, Ströher U. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol. 2004;78(10):5458–65. doi:10.1128/jvi.78.10.5458-5465.2004.
   PubMed Web of Science ®Google Scholar
• Reynolds P, Marzi A. Ebola and Marburg virus vaccines. Virus Genes. 2017;53(4):501–15. doi:10.1007/s11262-017-1455-x.
   PubMed Web of Science ®Google Scholar
• Ohimain EI. Recent advances in the development of vaccines for Ebola virus disease. Virus Res. 2016;211:174–85. doi:10.1016/j.virusres.2015.10.021.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-DiCaprio KM, Lewis MG, Geisbert JB, Grolla A, Leung A, Paragas J, Matthias L, Smith MA, Jones SM, et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008;4(11):e1000225. doi:10.1371/journal.ppat.1000225.
   PubMed Web of Science ®Google Scholar
• Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Ströher U, Grolla A, Bray M, Fritz EA, Fernando L, Feldmann F, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog. 2007;3(1):e2. doi:10.1371/journal.ppat.0030002.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-DiCaprio KM, Williams KJN, Geisbert JB, Leung A, Feldmann F, Hensley LE, Feldmann H, Jones SM. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol. 2008;82(11):5664–68. doi:10.1128/JVI.00456-08.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Hensley LE, Geisbert JB, Leung A, Johnson JC, Grolla A, Feldmann H. Postexposure treatment of Marburg virus infection. Emerg Infect Dis. 2010;16(7):1119–22. doi:10.3201/eid1607.100159.
   PubMed Web of Science ®Google Scholar
• Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Muñoz P, Moon JE, Ruck RC, Bennett JW, et al. A recombinant vesicular stomatitis virus Ebola vaccine. N Engl J Med. 2017;376(4):330–41. doi:10.1056/NEJMoa1414216.
   PubMed Web of Science ®Google Scholar
• Khurana S, Fuentes S, Coyle EM, Ravichandran S, Davey RT, Beigel JH. Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies. Nat Med. 2016;22(12):1439–47. doi:10.1038/nm.4201.
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer J-A, Kraehling V, Kasonta R, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med. 2016;374(17):1647–60. doi:10.1056/NEJMoa1502924.
   PubMed Web of Science ®Google Scholar
• Huttner A, Combescure C, Grillet S, Haks MC, Quinten E, Modoux C, Agnandji ST, Brosnahan J, Dayer J-A, Harandi AM, et al. A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa. Sci Transl Med. 2017;9(385):eaaj1701. doi:10.1126/scitranslmed.aaj1701.
   PubMed Web of Science ®Google Scholar
• Huttner A, Dayer J-A, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2015;15(10):1156–66. doi:10.1016/S1473-3099(15)00154-1.
   PubMed Web of Science ®Google Scholar
• Poetsch JH, Dahlke C, Zinser ME, Kasonta R, Lunemann S, Rechtien A, Ly ML, Stubbe HC, Krähling V, Biedenkopf N, et al. Detectable Vesicular Stomatitis Virus (VSV)-specific humoral and cellular immune responses following VSV-Ebola virus vaccination in humans. J Infect Dis. 2019;219(4):556–61. doi:10.1093/infdis/jiy565.
   PubMed Web of Science ®Google Scholar
• Rechtien A, Richert L, Lorenzo H, Martrus G, Hejblum B, Dahlke C, Kasonta R, Zinser M, Stubbe H, Matschl U, et al. Systems vaccinology identifies an early innate immune signature as a correlate of antibody responses to the Ebola vaccine rVSV-ZEBOV. Cell Rep. 2017;20(9):2251–61. doi:10.1016/j.celrep.2017.08.023.
   PubMed Web of Science ®Google Scholar
• Farooq F, Beck K, Paolino KM, Phillips R, Waters NC, Regules JA, Bergmann-Leitner ES. Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine. Sci Rep. 2016;6:27944. doi:10.1038/srep27944.
   PubMed Web of Science ®Google Scholar
• Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola). Lancet. 2017;389(10068):505–18. doi:10.1016/S0140-6736(16)32621-6.
   PubMed Web of Science ®Google Scholar
• Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Carroll MW, Doumbia M, Draguez B, Duraffour S, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386(9996):857–66. doi:10.1016/S0140-6736(15)61117-5.
   PubMed Web of Science ®Google Scholar
• Widdowson MS, Schrag SJ, Carter RJ, Carr W, Legardy-Williams J, Gibson L, Lisk DR, Jalloh MI, Bash-Taqi DA, Kargbo SA, et al. Implementing an Ebola vaccine study-Sierra Leone. MMWR Suppl. 2016:98–106. doi:10.15585/mmwr.su6503a14.
   PubMedGoogle Scholar
• Halperin SA, Arribas JR, Rupp R, Andrews CP, Chu L, Das R, Simon JK, Onorato MT, Liu K, Martin J, et al. Six-month safety data of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults. J Infect Dis. 2017;215(12):1789–98. doi:10.1093/infdis/jix189.
   PubMed Web of Science ®Google Scholar
• Kennedy SB, Bolay F, Kieh M, Grandits G, Badio M, Ballou R, Eckes R, Feinberg M, Follmann D, Grund B, et al. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. N Engl J Med. 2017;377(15):1438–47. doi:10.1056/NEJMoa1614067.
   PubMed Web of Science ®Google Scholar
• Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Dzharullaeva AS, Tukhvatulina NM, Shcheblyakov DV, Shmarov MM, Tokarskaya EA, Simakova YV, Egorova DA, et al. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: an open phase I/II trial in healthy adults in Russia. Hum Vaccin Immunother. 2017;13(3):613–20. doi:10.1080/21645515.2016.1238535.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Sullivan NJ, Graham BS. Chimpanzee adenovirus vector Ebola vaccine–preliminary report. N Engl J Med. 2015;373:776.
   PubMed Web of Science ®Google Scholar